#1 out of 5
business1d ago
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
- Europe’s pharma sector is losing market share to the U.S. and China amid new pricing and tariffs.
- U.S. tariffs and MFN pricing are pressuring European launches and investment decisions.
- China has become a major innovation engine, with a rising share of global biotech deals and pipeline.
- Europe’s R&D share has fallen from nearly half in 1990 to 26% today, per ING analysis.
- EU regulators and member states face internal barriers that slow access to medicines.
- EFPIA warns Europe must boost spending to keep companies and improve access to medicines.
- Spain emerges as a surprising clinical research hub amid EU biotech efforts.
- The EU introduced the Biotech and Critical Medicines acts to streamline trials and secure supply.
- EU's spending on medicines is about 1% of GDP, below U.S. and China levels.
- The U.S. remains the largest market for pharma firms, driving investment decisions.
Vote 0


